Amgen

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com

Amgen RSS Channel

Display # 
Title Published Date
Amgen Golden Ticket winners receive lab space and other benefits at QB3@953 22 June 2016
Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis 21 March 2016
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries 15 December 2015
FDA approves IMLYGICTM (talimogene laherparepvec) as first oncolytic viral therapy in the US 28 October 2015
Amgen to acquire privately-held Dezima Pharma 16 September 2015
Amgen and Xencor announce strategic collaboration in cancer immunotherapy and inflammation 16 September 2015
European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab) 23 July 2015
Amgen announces collaboration with Roche on cancer immunotherapy study with investigational medicines talimogene laherparepvec and atezolizumab 02 June 2015
Amgen receives FDA Breakthrough Therapy Designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia 01 July 2014
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma 05 February 2014
Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry 07 November 2013
Amgen's third quarter 2013 revenues increased 10 percent 24 October 2013
Amgen acquires Filgrastim franchise rights from Roche In 100 markets 22 October 2013
Amgen successfully completes Onyx Pharmaceuticals tender offer 02 October 2013
Amgen and ShanghaiTech University announce plans for Amgen China R&D center 25 September 2013
Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash 26 August 2013
FDA approves Amgen's XGEVA® (denosumab) for the treatment of giant cell tumor of bone 16 June 2013
Amgen and Astellas announce Japan Alliance 29 May 2013
Amgen and Zhejiang Beta Pharma announce planned joint venture in China 10 May 2013
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma 20 March 2013

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Exercise, future anticancer therapy…

Several studies have demonstrated the benefits of exercise to improve the quality of life of people with cancer. But Dr. Fred Saad, urologist-oncologist and researcher at...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]